Evaluation of adjuvant activities using human antigen presenting cells in vitro

Takehiro Higashi, Masatoshi Wakui, Kazuhisa Nakano, Kumiko Hashimoto, Rie Takagi, Yoshiya Tanaka, Sho Matsushita

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Immunomodulators such as lipopolysaccharides (LPS) and forskolin change the nature of dendritic cells (DCs) to induce Th1 and Th2 cells, respectively, thereby designated Th1 or Th2 adjuvants. Our previous study showed that such activities can be qualitatively evaluated by expression patterns of Notch ligand isoforms, using human monocyte-derived DCs and some leukemic cell lines, such as THP-1 or KG-1. However, quantitative evaluation of the adjuvant activities was not fully established. Methods: PMA-treated human monocytic cell line THP-1 was used as a target. Cells were stimulated with various adjuvants, and the intracellular levels of cAMP were determined. Results: Th2 adjuvant forskolin was qualitatively evaluated by an increased expression of Delta1 in PMA-treated THP-1 cells, as reported in our previous study. In PMA-treated THP-1 cells, intracellular cAMP levels increased after stimulation with forskolin, in a dose-dependent manner. On the other hand, LIPS, one of the known Th1 adjuvants, suppressed the increased cAMP level in a dose-dependent manner. Conclusions: Th2- and Th1-adjuvant activities can be quantitatively evaluated by using PMA-treated THP-1 cells and PMA-treated/ forskolin-stimulated THP-1 cells, respectively.

Original languageEnglish
Pages (from-to)219-222
Number of pages4
JournalAllergology International
Volume57
Issue number3
DOIs
Publication statusPublished - 2008
Externally publishedYes

Fingerprint

Antigen-Presenting Cells
Human Activities
Colforsin
Dendritic Cells
Cell Line
Th2 Cells
Th1 Cells
Immunologic Factors
Lipopolysaccharides
Monocytes
Protein Isoforms
In Vitro Techniques
Ligands

Keywords

  • Adjuvant
  • cAMP
  • Dendritic cells
  • Notch ligand
  • THP-1

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Higashi, T., Wakui, M., Nakano, K., Hashimoto, K., Takagi, R., Tanaka, Y., & Matsushita, S. (2008). Evaluation of adjuvant activities using human antigen presenting cells in vitro. Allergology International, 57(3), 219-222. https://doi.org/10.2332/allergolint.O-07-523

Evaluation of adjuvant activities using human antigen presenting cells in vitro. / Higashi, Takehiro; Wakui, Masatoshi; Nakano, Kazuhisa; Hashimoto, Kumiko; Takagi, Rie; Tanaka, Yoshiya; Matsushita, Sho.

In: Allergology International, Vol. 57, No. 3, 2008, p. 219-222.

Research output: Contribution to journalArticle

Higashi, T, Wakui, M, Nakano, K, Hashimoto, K, Takagi, R, Tanaka, Y & Matsushita, S 2008, 'Evaluation of adjuvant activities using human antigen presenting cells in vitro', Allergology International, vol. 57, no. 3, pp. 219-222. https://doi.org/10.2332/allergolint.O-07-523
Higashi, Takehiro ; Wakui, Masatoshi ; Nakano, Kazuhisa ; Hashimoto, Kumiko ; Takagi, Rie ; Tanaka, Yoshiya ; Matsushita, Sho. / Evaluation of adjuvant activities using human antigen presenting cells in vitro. In: Allergology International. 2008 ; Vol. 57, No. 3. pp. 219-222.
@article{72d6aa36ce6e41c5a6be73d7c82772d1,
title = "Evaluation of adjuvant activities using human antigen presenting cells in vitro",
abstract = "Background: Immunomodulators such as lipopolysaccharides (LPS) and forskolin change the nature of dendritic cells (DCs) to induce Th1 and Th2 cells, respectively, thereby designated Th1 or Th2 adjuvants. Our previous study showed that such activities can be qualitatively evaluated by expression patterns of Notch ligand isoforms, using human monocyte-derived DCs and some leukemic cell lines, such as THP-1 or KG-1. However, quantitative evaluation of the adjuvant activities was not fully established. Methods: PMA-treated human monocytic cell line THP-1 was used as a target. Cells were stimulated with various adjuvants, and the intracellular levels of cAMP were determined. Results: Th2 adjuvant forskolin was qualitatively evaluated by an increased expression of Delta1 in PMA-treated THP-1 cells, as reported in our previous study. In PMA-treated THP-1 cells, intracellular cAMP levels increased after stimulation with forskolin, in a dose-dependent manner. On the other hand, LIPS, one of the known Th1 adjuvants, suppressed the increased cAMP level in a dose-dependent manner. Conclusions: Th2- and Th1-adjuvant activities can be quantitatively evaluated by using PMA-treated THP-1 cells and PMA-treated/ forskolin-stimulated THP-1 cells, respectively.",
keywords = "Adjuvant, cAMP, Dendritic cells, Notch ligand, THP-1",
author = "Takehiro Higashi and Masatoshi Wakui and Kazuhisa Nakano and Kumiko Hashimoto and Rie Takagi and Yoshiya Tanaka and Sho Matsushita",
year = "2008",
doi = "10.2332/allergolint.O-07-523",
language = "English",
volume = "57",
pages = "219--222",
journal = "Allergology International",
issn = "1323-8930",
publisher = "Japanese Society of Allergology",
number = "3",

}

TY - JOUR

T1 - Evaluation of adjuvant activities using human antigen presenting cells in vitro

AU - Higashi, Takehiro

AU - Wakui, Masatoshi

AU - Nakano, Kazuhisa

AU - Hashimoto, Kumiko

AU - Takagi, Rie

AU - Tanaka, Yoshiya

AU - Matsushita, Sho

PY - 2008

Y1 - 2008

N2 - Background: Immunomodulators such as lipopolysaccharides (LPS) and forskolin change the nature of dendritic cells (DCs) to induce Th1 and Th2 cells, respectively, thereby designated Th1 or Th2 adjuvants. Our previous study showed that such activities can be qualitatively evaluated by expression patterns of Notch ligand isoforms, using human monocyte-derived DCs and some leukemic cell lines, such as THP-1 or KG-1. However, quantitative evaluation of the adjuvant activities was not fully established. Methods: PMA-treated human monocytic cell line THP-1 was used as a target. Cells were stimulated with various adjuvants, and the intracellular levels of cAMP were determined. Results: Th2 adjuvant forskolin was qualitatively evaluated by an increased expression of Delta1 in PMA-treated THP-1 cells, as reported in our previous study. In PMA-treated THP-1 cells, intracellular cAMP levels increased after stimulation with forskolin, in a dose-dependent manner. On the other hand, LIPS, one of the known Th1 adjuvants, suppressed the increased cAMP level in a dose-dependent manner. Conclusions: Th2- and Th1-adjuvant activities can be quantitatively evaluated by using PMA-treated THP-1 cells and PMA-treated/ forskolin-stimulated THP-1 cells, respectively.

AB - Background: Immunomodulators such as lipopolysaccharides (LPS) and forskolin change the nature of dendritic cells (DCs) to induce Th1 and Th2 cells, respectively, thereby designated Th1 or Th2 adjuvants. Our previous study showed that such activities can be qualitatively evaluated by expression patterns of Notch ligand isoforms, using human monocyte-derived DCs and some leukemic cell lines, such as THP-1 or KG-1. However, quantitative evaluation of the adjuvant activities was not fully established. Methods: PMA-treated human monocytic cell line THP-1 was used as a target. Cells were stimulated with various adjuvants, and the intracellular levels of cAMP were determined. Results: Th2 adjuvant forskolin was qualitatively evaluated by an increased expression of Delta1 in PMA-treated THP-1 cells, as reported in our previous study. In PMA-treated THP-1 cells, intracellular cAMP levels increased after stimulation with forskolin, in a dose-dependent manner. On the other hand, LIPS, one of the known Th1 adjuvants, suppressed the increased cAMP level in a dose-dependent manner. Conclusions: Th2- and Th1-adjuvant activities can be quantitatively evaluated by using PMA-treated THP-1 cells and PMA-treated/ forskolin-stimulated THP-1 cells, respectively.

KW - Adjuvant

KW - cAMP

KW - Dendritic cells

KW - Notch ligand

KW - THP-1

UR - http://www.scopus.com/inward/record.url?scp=53749098566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53749098566&partnerID=8YFLogxK

U2 - 10.2332/allergolint.O-07-523

DO - 10.2332/allergolint.O-07-523

M3 - Article

VL - 57

SP - 219

EP - 222

JO - Allergology International

JF - Allergology International

SN - 1323-8930

IS - 3

ER -